Earnings ·
Inogen reported second quarter 2026 revenue of $95.1 million, a 3.0% increase year-over-year, driven by international…
INGNInogen Inc
Inogen reported second quarter 2026 revenue of $95.1 million, a 3.0% increase year-over-year, driven by international demand and foreign exchange benefits. The company posted a GAAP net loss of $3.9 million compared to $4.2 million in the prior year period, while adjusted EBITDA rose 15.2% to $2.4 million. Management raised full-year 2026 adjusted EBITDA guidance to approximately $4.0 million and updated revenue expectations to a range of $355 million to $361 million. Operational highlights include the launch of the Rove 6 portable oxygen concentrator in Canada, completion of enrollment for the Simeox H SCOPE Study in China, and the appointment of Andy Reding as Chief Operating Officer. The company operates in the medical technology industry, developing and marketing innovative respiratory therapy devices for homecare settings.